Non-invasive assessment of programmed cell death ligand-1 expression using
Humans
B7-H1 Antigen
/ metabolism
Positron Emission Tomography Computed Tomography
/ methods
Esophageal Squamous Cell Carcinoma
/ diagnostic imaging
Fluorodeoxyglucose F18
Male
Esophageal Neoplasms
/ diagnostic imaging
Female
Middle Aged
Retrospective Studies
Aged
ROC Curve
Adult
Radiopharmaceuticals
18F-FDG PET-CT
Esophageal carcinoma
Metabolic tumor volume
PD-L1
Radiomics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2024
30 10 2024
Historique:
received:
23
02
2024
accepted:
24
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Programmed cell death ligand-1 (PD-L1) is an ideal checkpoint for immunohistochemical detection. The method of obtaining PD-L1 expression through biopsy can impact the accurate assessment of PD-L1 expression due to the spatial and temporal heterogeneity of tumors. Because of the limited sample size, biopsies often give only a localized picture of the tumor. In this retrospective study, a total of 2,386 metabolic tumor volume (MTV) features were extracted from
Identifiants
pubmed: 39478052
doi: 10.1038/s41598-024-77680-4
pii: 10.1038/s41598-024-77680-4
doi:
Substances chimiques
B7-H1 Antigen
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
CD274 protein, human
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26082Subventions
Organisme : The New Engineering Innovation Project of Hanshan Normal University
ID : XN201916
Organisme : The 2021 Science and Technology Plan Project of Jieyang Science and Technology Bureau
ID : skjcx061
Organisme : The 2021 Science and Technology Plan Project of Jieyang Science and Technology Bureau
ID : skjcx061
Informations de copyright
© 2024. The Author(s).
Références
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
doi: 10.3322/caac.21492
pubmed: 30207593
Lordick, F. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27, v50–v57. https://doi.org/10.1093/annonc/mdw329 (2016).
doi: 10.1093/annonc/mdw329
pubmed: 27664261
Normann, M. C. et al. Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. J Gynecol Oncol 30, e56. https://doi.org/10.3802/jgo.2019.30.e56 (2019).
doi: 10.3802/jgo.2019.30.e56
pubmed: 31074244
pmcid: 6543107
Wang, Z. & Wu, X. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Cancer Medicine 9, 8086–8121 (2020).
doi: 10.1002/cam4.3410
pubmed: 32875727
pmcid: 7643687
Wang, Y. et al. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. Acta Pharmaceutica Sinica B 11, 2957–2972 (2021).
doi: 10.1016/j.apsb.2021.03.004
pubmed: 34729298
pmcid: 8546663
Wu, Q., Qian, W., Sun, X. & Jiang, S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology & Oncology 15, 143 (2022).
doi: 10.1186/s13045-022-01362-9
Long, J. et al. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol 10, 146. https://doi.org/10.1186/s13045-017-0511-2 (2017).
doi: 10.1186/s13045-017-0511-2
pubmed: 28774337
pmcid: 5543600
Masopust, D. & Schenkel, J. M. The integration of T cell migration, differentiation and function. Nature Reviews Immunology 13, 309–320 (2013).
doi: 10.1038/nri3442
pubmed: 23598650
Ai, L., Xu, A. & Xu, J. Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol 1248, 33–59. https://doi.org/10.1007/978-981-15-3266-5_3 (2020).
doi: 10.1007/978-981-15-3266-5_3
pubmed: 32185706
Baba, Y. et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci 111, 3132–3141. https://doi.org/10.1111/cas.14541 (2020).
doi: 10.1111/cas.14541
pubmed: 32579769
pmcid: 7469863
Vivaldi, C. et al. Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? Int J Mol Sci 21. https://doi.org/10.3390/ijms21051658 (2020).
Zhao, J. J. et al. Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. Journal of Clinical Oncology 40, 392–402 (2022).
doi: 10.1200/JCO.21.01862
pubmed: 34860570
Stovgaard, E. et al. PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies. Breast Cancer Research and Treatment 181, 553–560 (2020).
doi: 10.1007/s10549-020-05655-w
pubmed: 32358635
Huisman, M. C. et al. Quantification of PD-L1 expression with 18F-BMS-986192 PET/CT in patients with advanced-stage non–small cell lung cancer. Journal of Nuclear Medicine 61, 1455–1460 (2020).
doi: 10.2967/jnumed.119.240895
pubmed: 32060213
Wang, D., Li, Y., Chen, X. & Li, P. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma. Medicine 100 (2021).
Monaco, L. et al. The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 49, 3401–3411. https://doi.org/10.1007/s00259-022-05783-z (2022).
doi: 10.1007/s00259-022-05783-z
pubmed: 35403860
Li, A. et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 5, 28. https://doi.org/10.1038/s41698-021-00165-4 (2021).
doi: 10.1038/s41698-021-00165-4
pubmed: 33772089
pmcid: 7997873
Zhou, K. I. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clinical Cancer Research 26, 6453–6463 (2020).
doi: 10.1158/1078-0432.CCR-20-2085
pubmed: 32820017
pmcid: 7744325
Heo, Y. J. et al. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. Pathol Res Pract 218, 153338. https://doi.org/10.1016/j.prp.2020.153338 (2021).
doi: 10.1016/j.prp.2020.153338
pubmed: 33440275
Wang, C. et al. Predicting EGFR and PD-L1 status in NSCLC patients using multitask AI system based on CT images. Frontiers in Immunology 13, 813072 (2022).
doi: 10.3389/fimmu.2022.813072
pubmed: 35250988
pmcid: 8895233
Yoon, J. et al. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. Thoracic Cancer 11, 993–1004 (2020).
doi: 10.1111/1759-7714.13352
pubmed: 32043309
pmcid: 7113038
Gong, X.-Q. et al. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma. Scientific Reports 13, 7710 (2023).
doi: 10.1038/s41598-023-34763-y
pubmed: 37173350
pmcid: 10182068
Kaira, K., Kuji, I. & Kagamu, H. Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging 21, 1–9 (2021).
doi: 10.1186/s40644-021-00381-y
Zhao, L., Liu, J., Wang, H. & Shi, J. Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. The British Journal of Radiology 94, 20200397 (2021).
doi: 10.1259/bjr.20200397
pubmed: 33492995
pmcid: 8011240
Mu, W. et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. Journal for immunotherapy of Cancer 9 (2021).
Rice, T. W., Ishwaran, H., Ferguson, M. K., Blackstone, E. H. & Goldstraw, P. Cancer of the Esophagus and Esophagogastric junction: An eighth edition staging primer. J Thorac Oncol 12, 36–42. https://doi.org/10.1016/j.jtho.2016.10.016 (2017).
Wang, T. A combined model for short-term wind speed forecasting based on empirical mode decomposition, feature selection, support vector regression and cross-validated lasso. PeerJ Computer Science 7, e732 (2021).
doi: 10.7717/peerj-cs.732
pubmed: 34712801
pmcid: 8507474
Wu, X. et al. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res 10, 51. https://doi.org/10.1186/s13550-020-00639-9 (2020).
doi: 10.1186/s13550-020-00639-9
pubmed: 32430866
pmcid: 7237589
Kuriyama, K. et al. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Cancer Sci 111, 1969–1978. https://doi.org/10.1111/cas.14421 (2020).
doi: 10.1111/cas.14421
pubmed: 32302443
pmcid: 7293073
Li, J., Ge, S., Sang, S., Hu, C. & Deng, S. Evaluation of PD-L1 expression level in patients with non-small cell lung cancer by 18F-FDG PET/CT radiomics and clinicopathological characteristics. Frontiers in Oncology 11, 789014 (2021).
doi: 10.3389/fonc.2021.789014
pubmed: 34976829
pmcid: 8716940
Jiang, M. et al. Assessing PD-L1 expression level by radiomic features from PET/CT in nonsmall cell lung cancer patients: an initial result. Academic Radiology 27, 171–179 (2020).
doi: 10.1016/j.acra.2019.04.016
pubmed: 31147234
Zheng, Y.-M. et al. A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma. European Journal of Radiology 146, 110093 (2022).
doi: 10.1016/j.ejrad.2021.110093
pubmed: 34890937
Paquet, N., Albert, A., Foidart, J. & Hustinx, R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45, 784–788 (2004).
pubmed: 15136627
Lowekamp, B. C., Chen, D. T., Ibáñez, L. & Blezek, D. The design of SimpleITK. Frontiers in Neuroinformatics 7, 45 (2013).
doi: 10.3389/fninf.2013.00045
pubmed: 24416015
pmcid: 3874546
Fedorov, A. et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magnetic Resonance Imaging 30, 1323–1341 (2012).
doi: 10.1016/j.mri.2012.05.001
pubmed: 22770690
pmcid: 3466397
Van Griethuysen, J. J. et al. Computational radiomics system to decode the radiographic phenotype. Cancer Research 77, e104–e107 (2017).
doi: 10.1158/0008-5472.CAN-17-0339
pubmed: 29092951
pmcid: 5672828
Aerts, H. J. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5, 4006. https://doi.org/10.1038/ncomms5006 (2014).
doi: 10.1038/ncomms5006
pubmed: 24892406
Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Medical Decision Making 26, 565–574 (2006).
doi: 10.1177/0272989X06295361
pubmed: 17099194
pmcid: 2577036